ES2167453T3 - Composicion de suministro medicamentoso que contiene quitosano o derivado del mismo con un potencial z. definido. - Google Patents

Composicion de suministro medicamentoso que contiene quitosano o derivado del mismo con un potencial z. definido.

Info

Publication number
ES2167453T3
ES2167453T3 ES95929164T ES95929164T ES2167453T3 ES 2167453 T3 ES2167453 T3 ES 2167453T3 ES 95929164 T ES95929164 T ES 95929164T ES 95929164 T ES95929164 T ES 95929164T ES 2167453 T3 ES2167453 T3 ES 2167453T3
Authority
ES
Spain
Prior art keywords
chitosane
derivative
potential
same
composition containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95929164T
Other languages
English (en)
Inventor
Peter James Watts
Lisbeth Illum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Services Ltd
Original Assignee
West Pharmaceutical Services Drug Delivery and Clinical Research Center Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by West Pharmaceutical Services Drug Delivery and Clinical Research Center Ltd filed Critical West Pharmaceutical Services Drug Delivery and Clinical Research Center Ltd
Application granted granted Critical
Publication of ES2167453T3 publication Critical patent/ES2167453T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

SE FACILITA UNA COMPOSICION DE SUMINISTRO MEDICAMENTOSO PARA LA ADMINISTRACION EN LA MUCOSA. LA COMPOSICION INCLUYE UN COMPUESTO Y PARTICULAS ACTIVAS FARMACOLOGICAMENTE, PREFERIBLEMENTE EN POLVO O MICROESFERAS, DE QUITOSANO O DERIVADO DE QUITOSANO O SAL EN LA QUE LAS PARTICULAS SE HALLAN BIEN SOLIDIFICADAS O PARCIALMENTE ENLAZADAS DE FORMA CRUZADA DE FORMA QUE TIENEN UN POTENCIAL-ZETA DE +0.5 A +50MV. LAS PARTICULAS SOLIDIFICADAS SE HACEN MEDIANTE EL TRATAMIENTO DE LAS PARTICULAS MEDIANTE UNA SAL DE QUITOSANO SOLUBLE EN AGUA CON UN AGENTE ALCALINO COMO EL HIDROXIDO DE SODIO EN AGUA QUE NO CONTIENE ACIDO PARA HACERLAS INSOLUBLES.
ES95929164T 1994-08-20 1995-08-21 Composicion de suministro medicamentoso que contiene quitosano o derivado del mismo con un potencial z. definido. Expired - Lifetime ES2167453T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9416884A GB9416884D0 (en) 1994-08-20 1994-08-20 Drug delivery compositions

Publications (1)

Publication Number Publication Date
ES2167453T3 true ES2167453T3 (es) 2002-05-16

Family

ID=10760170

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95929164T Expired - Lifetime ES2167453T3 (es) 1994-08-20 1995-08-21 Composicion de suministro medicamentoso que contiene quitosano o derivado del mismo con un potencial z. definido.

Country Status (13)

Country Link
US (1) US5840341A (es)
EP (1) EP0776195B1 (es)
JP (1) JPH10508004A (es)
AT (1) ATE208193T1 (es)
AU (1) AU688566B2 (es)
DE (1) DE69523765T2 (es)
DK (1) DK0776195T3 (es)
ES (1) ES2167453T3 (es)
FI (1) FI970694A (es)
GB (2) GB9416884D0 (es)
NO (1) NO315636B1 (es)
PT (1) PT776195E (es)
WO (1) WO1996005810A1 (es)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3098401B2 (ja) * 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤
CA2257408A1 (en) * 1996-07-10 1998-01-15 Lisbeth Illum Compositions suitable for delivery of genes to epithelial cells
US6649192B2 (en) * 1996-07-29 2003-11-18 Universidade De Santiago De Compostela Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms
ES2114502B1 (es) * 1996-07-29 1999-07-01 Univ Santiago Compostela Aplicacion de nanoparticulas a base de polimeros hidrofilicos como formas farmaceuticas.
GB9700624D0 (en) 1997-01-14 1997-03-05 Danbiosyst Uk Drug delivery composition
DE19712978A1 (de) * 1997-03-27 1998-10-01 Henkel Kgaa Chitosanmikrosphären
EP1010435B1 (en) * 1997-09-05 2010-11-03 Maruho K.K. Nanocapsule preparations for treating intraarticular diseases
DE19756314C2 (de) * 1997-12-12 2000-06-29 Roland Bodmeier Zubereitung mit verlängerter Verweildauer am Applikationsort
JPH11246392A (ja) * 1998-03-03 1999-09-14 Makoto Otsuka 経口用固形製剤
KR100306221B1 (ko) * 1998-12-17 2002-03-21 김충섭 서방성키토산미세캡슐의제조방법
GB9905136D0 (en) 1999-03-06 1999-04-28 Danbiosyst Uk Surface modification of lamellar particles
PT1808438E (pt) 1999-06-29 2015-01-14 Mannkind Corp Purificação e estabilização de péptidos e proteínas em agentes farmacêuticos
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
WO2001024795A1 (de) * 1999-10-01 2001-04-12 Skw Trostberg Aktiengesellschaft α-LIPONSÄURE(-DERIVATE)ENTHALTENDE RETARDFORM
GB9924797D0 (en) * 1999-10-20 1999-12-22 West Pharm Serv Drug Res Ltd Compound
US20030206958A1 (en) * 2000-12-22 2003-11-06 Cattaneo Maurizio V. Chitosan biopolymer for the topical delivery of active agents
EP1278512A2 (en) * 2000-05-03 2003-01-29 MBT Munich Biotechnology AG Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
GB2378383A (en) * 2001-06-06 2003-02-12 Gursharan Moonga Nasal delivery of pharmaceutical compositions in powder form
US20030134810A1 (en) * 2001-10-09 2003-07-17 Chris Springate Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents
US20030224000A1 (en) * 2001-12-21 2003-12-04 Kokai-Kun John Fitzgerald Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies
AU2003207508A1 (en) * 2002-01-10 2003-07-30 Northeastern University Hybrid immobilized catalytic system with controlled permeability
ATE385193T1 (de) 2002-03-20 2008-02-15 Mannkind Corp Inhalationsgerät
AU2003270427A1 (en) * 2002-09-06 2004-03-29 University Of South Florida Cellular delivery of natriuretic peptides
AU2003268531A1 (en) * 2002-09-06 2004-03-29 University Of South Florida Materials and methods for treatment of allergic diseases
US20080214437A1 (en) * 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
GB0302738D0 (en) * 2003-02-06 2003-03-12 Advanced Biopolymers As Composition
JP2006525354A (ja) * 2003-05-01 2006-11-09 アルキメデス・ディヴェロップメント・リミテッド Ｌｈ−ｒｈアナログロイプロイドの経鼻投与
GB0315632D0 (en) 2003-07-04 2003-08-13 West Pharm Serv Drug Res Ltd Pharmaceutical formulations
US20050147581A1 (en) * 2003-11-19 2005-07-07 The Board Of Trustees Of The University Of Illinois Macromolecular drug complexes having improved stability and therapeutic use of the same
US20050175679A1 (en) * 2004-02-10 2005-08-11 Michael Moshman Controlled release formulations
WO2005094420A2 (en) * 2004-02-17 2005-10-13 University Of South Florida Materials and methods for treatment of inflammatory and cell proliferation disorders
CA2565236A1 (en) * 2004-05-06 2005-11-17 Ivrea Pharmaceuticals, Inc. Particles for the delivery of active agents
CA2575692C (en) 2004-08-20 2014-10-14 Mannkind Corporation Catalysis of diketopiperazine synthesis
BR122019022692B1 (pt) 2004-08-23 2023-01-10 Mannkind Corporation Composição terapêutica em pó seco contendo dicetopiperazina, pelo menos um tipo de cátion e um agente biologicamente ativo
US7892414B1 (en) 2004-11-19 2011-02-22 The United States Of America As Represented By The Secretary Of Army Electrochemical biosensors, applications and methods of making biosensors
ES2277743B2 (es) * 2005-06-02 2008-12-16 Universidade De Santiago De Compostela Nanoparticulas que comprenden quitosano y ciclodextrina.
DK1937219T3 (en) 2005-09-14 2016-02-15 Mannkind Corp A method for drug formulation based on increasing the affinity of the crystalline surfaces of the microparticle of active principles
IN2015DN00888A (es) 2006-02-22 2015-07-10 Mannkind Corp
WO2008020318A2 (en) * 2006-03-30 2008-02-21 Engene, Inc. Non-viral compositions and methods for transfecting gut cells in vivo
EP2051585A4 (en) * 2006-04-28 2010-06-02 Univ South Florida MATERIALS AND METHODS OF SUPPRESSING INFLAMMATION THROUGH INHIBITION OF THE VORHOF RECEPTOR FOR NATRIURETIC PEPTIDES
PT2028937E (pt) * 2006-05-22 2015-04-09 Vanda Pharmaceuticals Inc Tratamento por agonista de melatonina
CN101148511B (zh) * 2006-09-18 2010-10-20 中国科学院过程工程研究所 荧光壳聚糖微球的制备方法及其在示踪剂领域的应用
US20100028447A1 (en) 2007-01-22 2010-02-04 Targacept, Inc. Intranasal, Buccal, And Sublingual Administration Of Metanicotine Analogs
ES2619181T3 (es) 2007-08-28 2017-06-23 Otago Innovation Limited Hidrogel quirúrgico
GB0716907D0 (en) 2007-08-31 2007-10-10 Archimedes Dev Ltd Pharmaceutical powder compositions
EP2057982A1 (en) 2007-11-09 2009-05-13 Archimedes Development Limited Intranasal compositions
AU2009240512B2 (en) * 2008-04-24 2014-07-10 Medtronic, Inc. Protective gel based on chitosan and oxidized polysaccharide
AU2009240509B2 (en) 2008-04-24 2014-08-21 Medtronic, Inc. Rehydratable thiolated polysaccharide particles and sponge
US8530632B2 (en) 2008-04-24 2013-09-10 Medtronic Xomed, Inc. Chitosan-containing protective composition
US8802652B2 (en) 2008-04-24 2014-08-12 Medtronic, Inc. Rehydratable polysaccharide particles and sponge
EP2123261A1 (en) * 2008-05-20 2009-11-25 Stallergenes S.A. Mucoadhesive particulate formulation for inducing antigen-specific immune tolerance
KR101933816B1 (ko) 2008-06-13 2019-03-29 맨카인드 코포레이션 건조 분말 흡입기 및 약물 투여 시스템
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
EP2609954B1 (en) 2008-06-20 2021-12-29 MannKind Corporation An interactive apparatus for real-time profiling of inhalation efforts
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
JP2009149675A (ja) * 2009-02-24 2009-07-09 Novadel Pharma Inc 極性または非極性の、バッカルスプレーまたはカプセル
US8538707B2 (en) 2009-03-11 2013-09-17 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
MY157166A (en) 2009-06-12 2016-05-13 Mankind Corp Diketopiperazine microparticles with defined specific surface areas
JP5784622B2 (ja) 2009-11-03 2015-09-24 マンカインド コーポレ−ション 吸入活動をシミュレートするための装置及び方法
RU2531455C2 (ru) 2010-06-21 2014-10-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
JP6133270B2 (ja) 2011-04-01 2017-05-24 マンカインド コーポレイション 薬剤カートリッジのためのブリスター包装
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
CA2852536A1 (en) 2011-10-24 2013-05-02 Mannkind Corporation Methods and compositions for treating pain
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
KR102411809B1 (ko) 2012-01-26 2022-06-22 반다 파마슈티칼즈, 인코퍼레이티드. 일주기 리듬 장애의 치료
ES2624294T3 (es) 2012-07-12 2017-07-13 Mannkind Corporation Sistemas de suministro de fármacos en polvo seco
EP2911690A1 (en) 2012-10-26 2015-09-02 MannKind Corporation Inhalable influenza vaccine compositions and methods
EP3767297A1 (en) 2012-12-18 2021-01-20 Vanda Pharmaceuticals Inc. Method of determining tau and thereby determining whether a patient has a free-running circadian rhythm
EP2970149B1 (en) 2013-03-15 2019-08-21 MannKind Corporation Microcrystalline diketopiperazine compositions and methods
CA2908232A1 (en) * 2013-03-26 2014-10-02 Optinose As Nasal administration of fluticasone and carbon dioxide
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
BR112016000937A8 (pt) 2013-07-18 2021-06-22 Mannkind Corp formulações farmacêuticas de pó seco, método para a fabricação de uma formulação de pó seco e uso de uma formulação farmacêutica de pó seco
CA2920488C (en) 2013-08-05 2022-04-26 Mannkind Corporation Insufflation apparatus and methods
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
JP6945614B2 (ja) * 2014-03-26 2021-10-06 オプティノーズ アズ 経鼻投与
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
CN106470724A (zh) * 2014-06-25 2017-03-01 奥普蒂诺斯公司 鼻腔给药
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
JOP20180128A1 (ar) * 2018-12-24 2020-06-24 Univ Of Petra صيغة دوائية صلبة قابلة للتشتت في الفم

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4895724A (en) * 1985-06-07 1990-01-23 Pfizer Inc. Chitosan compositions for controlled and prolonged release of macromolecules
US5129877A (en) * 1988-04-29 1992-07-14 University Of Georgia Research Foundation, Inc. Receptor-mediated delivery system
GB8904370D0 (en) * 1989-02-25 1989-04-12 Cosmas Damian Ltd Liquid delivery compositions
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration

Also Published As

Publication number Publication date
FI970694A0 (fi) 1997-02-19
PT776195E (pt) 2002-04-29
GB9416884D0 (en) 1994-10-12
FI970694A (fi) 1997-02-19
NO970507L (no) 1997-02-05
NO970507D0 (no) 1997-02-05
GB2305124A (en) 1997-04-02
ATE208193T1 (de) 2001-11-15
GB2305124B (en) 1998-11-18
DK0776195T3 (da) 2001-12-27
AU3262695A (en) 1996-03-14
JPH10508004A (ja) 1998-08-04
EP0776195A1 (en) 1997-06-04
WO1996005810A1 (en) 1996-02-29
EP0776195B1 (en) 2001-11-07
NO315636B1 (no) 2003-10-06
DE69523765D1 (de) 2001-12-13
GB9702503D0 (en) 1997-03-26
US5840341A (en) 1998-11-24
DE69523765T2 (de) 2002-09-26
AU688566B2 (en) 1998-03-12

Similar Documents

Publication Publication Date Title
ES2167453T3 (es) Composicion de suministro medicamentoso que contiene quitosano o derivado del mismo con un potencial z. definido.
MX9300110A (es) Preparacion farmaceutica en la forma de una tableta de efervescencia o de desintegracion o de un granulado de tipo instanteneo y procedimiento para su preparacion.
UA26455C2 (uk) Лікарський препарат у формі таблеток із сповільhеhим вивільhеhhям активhого іhгредієhта
ES2155931T3 (es) Forma de administracion de un agente activo de liberacion prolongada en banda.
ES2125099T3 (es) Composiciones que comprenden nanoparticulas de un antiinflamatorio no estereoideo.
ES2137350T3 (es) Formulacion farmaceutica.
BR9710115A (pt) Processo para aplicar partìculas sólidas de um medicamento em superfìcies de mucosa das cavidade nasais, composição aquosa farmacêutica, e , processo de preparação de uma composição aquosa farmacêutica.
CL2004001182A1 (es) Composicion farmaceutica que comprende a una microparticula de liberacion sostenida la que contiene a un derivado de 1,2 benzazol; procedimiento de preparacion de la microparticula; util como broncodilatador, antipsicoticos y en otros problemas del s
IL120317A0 (en) Otic antibacterial compositions
RS49764B (sr) Farmaceutski preparat za primenu na mukozu
ID28510A (id) Formulasi oral yang baru untuk agonis atau antagonis 5-ht4
ES2072647T3 (es) Composiciones que contienen sales de ranitidina/carboxilato de bismuto.
PE22995A1 (es) Composicion de tiotepa liofilizada estable
PE33396A1 (es) Composicion para el tratamiento del ansia de nicotina y/o los sintomas de abstinencia de fumar
CO5640085A2 (es) Formulaciones farmaceuticas que comprenden amoxicilina y clavulanato
DE69408579D1 (de) Asserlösliche pharmazeutische zusammensetzungen, die östronderivate und kalziumsalze enthalten
ES2067052T3 (es) Procedimiento para el tratamiento final de tensioactivos anfoteros o zwitterionicos.
HUP9902415A2 (hu) Azonnal felszabaduló szilárd beadási formák és eljárás azok előállítására
GR3018337T3 (en) Topical application composition.
AR040279A2 (es) Composiciones que contiene sal de sertralina
ES2186415T3 (es) Composiciones detergentes y para ablandar el agua.
ES2149736T1 (es) Composiciones farmaceuticas conteniendo derivados de tienopiridina estables y libres de antioxidantes.
AR044697A1 (es) Formulaciones farmaceuticas que comprenden amoxicilina y clavulanato
BR9914336A (pt) Tablete de uma composição particulada compactada, e, uso do acetato de sódio
GR77250B (es)